LitAlert ~~ GeneLit.com

    • Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
    • Yoshihama T, Kuroda Y, Chiyoda T, Takahashi M, Yoshimura T, Saotome K, Nanki Y, Sakai K, Kobayashi Y, Yamagami W, Aoki D.
    • Int J Clin Oncol. 2022 Jul 15. doi: 10.1007/s10147-022-02212-x. Epub ahead of print.
    • Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.
    • Chen F, Park SL, Wilkens LR, Wan P, Hart SN, Hu C, Yadav SS, Couch FJ, Conti DV, de Smith AJ, Haiman CA.
    • Cancer Res. 2022 Jul 14:can.21.4461. doi: 10.1158/0008-5472.CAN-21-4461. Epub ahead of print.
    • Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
    • Pietzak EJ, Whiting K, Srinivasan P, Bandlamudi C, Khurram A, Joseph V, Walasek A, Bochner E, Clinton T, Almassi N, Truong H, de Jesus Escano MR, Wiseman M, Mandelker D, Kemel Y, Zhang L, Walsh MF, Cadoo KA, Coleman JA, Al-Ahmadie H, Rosenberg JE, Iyer GV, Solit DB, Ostrovnaya I, Offit K, Robson ME, Stadler ZK, Berger MF, Bajorin DF, Carlo M, Bochner BH.
    • Clin Cancer Res. 2022 Jul 14:ccr.22.1006. doi: 10.1158/1078-0432.CCR-22-1006. Epub ahead of print.
    • Double heterozygous pathogenic variants prevalence in a cohort of hereditary breast cancer patients.
    • Megid TB, Barros-Filho MC, Pisani JP, Achatz MI.
    • Front Oncol. 2022 Jul 14;12:873395. doi: 10.3389/fonc.2022.873395.
    • Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation.
    • Shammas N, Yang T, Abidi A, Amneus M, Hodeib M.
    • Gynecol Oncol Rep. 2022 Jul 14;101044. doi: 10.1016/j.gore.2022.101044.
    • Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, Bordia S, McGuinness D, Cui K, Locker GY, Golan T.
    • J Clin Oncol. 2022 Jul 14:JCO2101604. doi: 10.1200/JCO.21.01604. Epub ahead of print.
    • Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis.
    • Kar SP, Quiros PM, Gu M, Jiang T, Mitchell J, Langdon R, Iyer V, Barcena C, Vijayabaskar MS, Fabre MA, Carter P, Petrovski S, Burgess S, Vassiliou GS.
    • Nat Genet. 2022 Jul 14. doi: 10.1038/s41588-022-01121-z. Epub ahead of print.
    • Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jul 14.
    • Research news

    Original research:

    PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.

    • Incidence of other cancer diagnoses in women with breast cancer: a retrospective cohort study with 42,248 women.
    • Nikolov I, Kostev K, Kalder M.
    • Breast Cancer Res Treat. 2022 Jul 12. doi: 10.1007/s10549-022-06666-5. Epub ahead of print.
    • BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.
    • Symonds L, Konnick E, Vakar-Lopez F, Cheng HH, Schweizer MT, Nelson PS, Pritchard CC, Montgomery B.
    • JCO Precis Oncol. 2022 Jul;6:e2200091. doi: 10.1200/PO.22.00091.
    • Case report